JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by ...

Global sales of Opdivo were higher in the third quarter ... but 1 percentage point of Bristol revenue growth is about $500 million. And that's the amount that Bristol is increasing its guidance ...

Opdivo revenue also grew 10% year over year ... This is among the highest growth rates among S&P 500 REITs. VICI also announced and originated $1.8 billion in acquisitions for the year.

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, ...

It’s essential to move out of S&P 500 index funds and concentrate on ultra ... an oral immunomodulatory drug for the treatment of multiple myeloma Opdivo for anti-cancer indications Eliquis ...

Keytruda, Opdivo, and Tencentriq are all blockbuster ... In early 2023, it handed Akeso $500 million upfront for exclusive rights to ivonescimab outside of China. Akeso is still eligible to ...

The move affects around 500 employees, and will allow Nektar to ... three clinical trials in combination with PD-1 inhibitor Opdivo (nivolumab) in melanoma, renal cell carcinoma and urothelial ...